Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Receivables - Other (2016)

Historic Receivables - Other for Northwest Biotherapeutics (NWBO) over the last 5 years, with Q3 2016 value amounting to $700000.0.

  • Northwest Biotherapeutics' Receivables - Other fell 4166.67% to $700000.0 in Q3 2016 from the same period last year, while for Sep 2016 it was $700000.0, marking a year-over-year decrease of 4166.67%. This contributed to the annual value of $1.2 million for FY2015, which is N/A changed from last year.
  • According to the latest figures from Q3 2016, Northwest Biotherapeutics' Receivables - Other is $700000.0, which was down 4166.67% from $1.0 million recorded in Q2 2016.
  • Northwest Biotherapeutics' 5-year Receivables - Other high stood at $4.8 million for Q3 2012, and its period low was $700000.0 during Q3 2016.
  • Moreover, its 4-year median value for Receivables - Other was $1.2 million (2015), whereas its average is $2.0 million.
  • Per our database at Business Quant, Northwest Biotherapeutics' Receivables - Other crashed by 5428.57% in 2015 and then tumbled by 4166.67% in 2016.
  • Over the past 4 years, Northwest Biotherapeutics' Receivables - Other (Quarter) stood at $4.8 million in 2012, then crashed by 45.31% to $2.6 million in 2014, then tumbled by 54.29% to $1.2 million in 2015, then tumbled by 41.67% to $700000.0 in 2016.
  • Its Receivables - Other was $700000.0 in Q3 2016, compared to $1.0 million in Q2 2016 and $1.0 million in Q1 2016.